Cargando...

Mogamulizumab for the treatment of cutaneous T-cell lymphoma: recent advances and clinical potential

Mogamulizumab (KW-0761) is a humanized immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets CC chemokine receptor 4 (CCR4). It has shown promising therapeutic potential in phase I and II clinical trials and is currently being investigated for efficacy in treating cutaneous T-cell lymphoma...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Ther Adv Hematol
Autores principales: Duvic, Madeleine, Evans, Mark, Wang, Casey
Formato: Artigo
Lenguaje:Inglês
Publicado: SAGE Publications 2016
Materias:
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4872175/
https://ncbi.nlm.nih.gov/pubmed/27247757
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620716636541
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!